Rheumatoid Arthritis Drugs Market Introduction and Overview
According to SPER Market Research, the Global Rheumatoid Arthritis Drugs Market is estimated to reach USD 78718.42 million by 2033 with a CAGR of 3.8%.
The report includes an in-depth analysis of the Global Rheumatoid Arthritis Drugs Market, including market size and trends, product mix, Applications, and supplier analysis. An autoimmune condition that causes the body's immune system to target its own tissues, including joints, is known as rheumatoid arthritis. Painful joint stiffness and edema result from this. An anti-rheumatic medicine is a pharmaceutical used to treat rheumatoid arthritis. It is a condition that affects people of all ages, although it is especially likely to strike the elderly. Joint discomfort, stiffness, soreness, and swelling are all signs of rheumatoid arthritis. At the moment, rheumatoid arthritis has no known cure. Nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, disease-modifying anti-rheumatic medications (DMARDs), and uric acid medications are among the medications that are effectively used to manage the symptoms of rheumatoid arthritis.
- Biocon Biologics Ltd., a division of Biocon Ltd., declared in July 2023 that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), would be available in the United States for the management of rheumatoid arthritis.
- Pfizer Inc. stated in February 2022 that the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), an interchangeable biosimilar to Humira (adalimumab), has been accepted for consideration by the U.S. Food and Drug Administration (FDA).
- A commercialization and license agreement was signed in February 2022 by Biogen Inc. and Xbrane Biopharma AB for the development, production, and marketing of Xcimzane, a preclinical monoclonal antibody that is a potential biosimilar to CIMZIA (certolizumab pegol).
Market Opportunities and Challenges
The rise in rheumatoid arthritis prevalence, the rise in demand for rheumatoid arthritis drugs, the expiration of patents and the introduction of biosimilar drugs, the aging of the population, the increase in the use of conventional DMARDs, and government campaigns to increase awareness of rheumatoid arthritis symptoms are the main factors propelling the growth of the rheumatoid arthritis drugs market. Other factors that support market expansion include advancements in advanced biologics, an increase in healthcare spending, a rise in purchasing power, and the availability of high-quality medications to middle-class and lower-class families worldwide. Conversely, during the projected period, the market for rheumatoid arthritis medications is expected to have strong growth potential due to increased awareness of the need of early detection and treatment of rheumatoid arthritis.
The availability of natural treatments for rheumatoid arthritis and non-drug pain management methods would impede the market's recent expansion and development. Acupuncture, Tai-chi, and other natural therapies are becoming more and more well-liked in society. Acupuncture is quickly making a name for itself as a common pain therapy, according to studies. Numerous ailments, such as fibromyalgia, arthritis, back pain, sprains, and sports-related injuries, can be treated with acupuncture. An ancient martial practice called tai-chi is beneficial in managing rheumatoid arthritis. Deep breathing and slow, soft motions are key components in tai chi. Furthermore, applying topical creams, lotions, and gels directly to the skin can assist relieve discomfort.
Market Competitive Landscape
There are a number of significant businesses in the competitive and fragmented rheumatoid arthritis drug industry. AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company are a few of the top companies in the sector.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Drug Class Type, By Route of Administration, By Sales Channel, By Distribution Channel
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | AbbVie Inc, Johnson & Johnson Innovative Medicine, Amgen Inc, Pfizer Inc, Novartis AG, Sanofi S.A, F. Hoffmann-La Roche Ltd, Merck & Co, Inc, Bristol-Myers Squibb Company, and Eli Lilly and Company.
|
COVID-19 Impact on Global Rheumatoid Arthritis Drugs Market
The COVID-19 epidemic was deemed a public health emergency of international concern by the World Health Organization (WHO) on January 30, 2020. Globally, COVID-19 has impacted almost 210 countries. Patients with rheumatoid arthritis who have COVID-19 infection may be more likely to experience severe symptoms and other problems, according to the Lancet Rheumatology 2020. Certain DMARDs, including the medication hydroxychloroquine, are frequently used to treat rheumatoid arthritis, and they are being studied as possible COVID-19 therapies. Additionally, patients with COVID-19 are being evaluated for other commonly used treatments such biologics that target interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra). Consequently, during the anticipated period, the COVID-19 infection increased growth potential for producers of medications for rheumatoid arthritis.
Key Target Audience:
- Pharmaceutical Drug Manufacturer
- Rheumatoid Arthritis Treatment Centers
- Research and Development (R&D) Companies
- Government Research Laboratories
- Government Authorities and R&D Institutions
- Academic & Medical Research Institutions
Our in-depth analysis of the Rheumatoid Arthritis Drugs Market includes the following segments:
|
By Drug Class Type:
|
Disease-modifying Anti-Rheumatic Drugs (DMARDs)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Uric Acid Drugs
|
|
By Route of Administration:
|
Oral
Parenteral
|
|
By Sales Channel:
|
Prescription-based Drugs
Over-the-counter Drugs
|
|
By Distribution Channel:
|
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
|
Key Topics Covered in the Report:
- Global Rheumatoid Arthritis Drugs Market Size (FY’2024-FY’2033)
- Overview of Global Rheumatoid Arthritis Drugs Market
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Drug Class Type (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Route of Administration (Oral, Parenteral)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Sales Channel (Prescription-based Drugs, Over-the-counter Drugs)
- Segmentation of Global Rheumatoid Arthritis Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
- Statistical Snap of Global Rheumatoid Arthritis Drugs Market
- Expansion Analysis of Global Rheumatoid Arthritis Drugs Market
- Problems and Obstacles in Global Rheumatoid Arthritis Drugs Market
- Competitive Landscape in the Global Rheumatoid Arthritis Drugs Market
- Impact of COVID-19 and Demonetization on Global Rheumatoid Arthritis Drugs Market
- Details on Current Investment in Global Rheumatoid Arthritis Drugs Market
- Competitive Analysis of Global Rheumatoid Arthritis Drugs Market
- Prominent Players in the Global Rheumatoid Arthritis Drugs Market
- SWOT Analysis of Global Rheumatoid Arthritis Drugs Market
- Global Rheumatoid Arthritis Drugs Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Rheumatoid Arthritis Drugs Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Rheumatoid Arthritis Drugs Market Manufacturing Base Distribution, Sales Area, Ingredients
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Rheumatoid Arthritis Drugs Market
7. Global Rheumatoid Arthritis Drugs Market, By Drug Class Type (USD Million) 2020-2033
7.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2020-2026
7.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Drug Class Type, 2027-2033
7.3. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
7.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
7.5. Corticosteroids
7.6. Uric Acid Drugs
7.7. Others
8. Global Rheumatoid Arthritis Drugs Market, By Route of Administration (USD Million) 2020-2033
8.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2020-2026
8.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Route of Administration, 2027-2033
8.3. Oral
8.4. Parenteral
9. Global Rheumatoid Arthritis Drugs Market, By Sales Channel (USD Million) 2020-2033
9.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2020-2026
9.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Sales Channel, 2027-2033
9.3. Prescription-based Drugs
9.4. Over-the-counter Drugs
10. Global Rheumatoid Arthritis Drugs Market, By Distribution Channel (USD Million) 2020-2033
10.1. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2020-2026
10.2. Global Rheumatoid Arthritis Drugs Market Size, Share and Forecast, By Distribution Channel, 2027-2033
10.3. Hospital Pharmacy
10.4. Retail Pharmacy
10.5. Online Pharmacy
11. Global Rheumatoid Arthritis Drugs Market, Forecast, 2020-2033 (USD Million)
11.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share
12. Global Rheumatoid Arthritis Drugs Market, By Region, 2020-2033 (USD Million)
12.1. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2020-2026)
12.2. Global Rheumatoid Arthritis Drugs Market Size and Market Share, By Region (2027-2033)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Qatar
12.5.4. South Africa
12.5.5. Egypt
12.5.6. Morocco
12.5.7. Nigeria
12.5.8. Rest of Middle-East and Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America
13. Company Profile
13.1. AbbVie Inc.
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Johnson & Johnson Innovative Medicine
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Amgen Inc.
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Pfizer Inc.
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Novartis AG
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Sanofi S.A.
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. F. Hoffmann-La Roche Ltd.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Merck & Co., Inc.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Bristol-Myers Squibb Company
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Eli Lilly and Company
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope